Abstract |
Twenty-six patients with far-advanced, refractory breast cancer were treated iv with vindesine (DVA) at a dose of 3 mg/m2/week. In 21 evaluable patients there were six partial remissions. Four patients who did not respond after at least four doses of intermittent DVA received continuous-infusion DVA at a dose of 1.5 mg/m2/day X 2 every other week; none responded. Five of the six responders had had disease progression on other vinca alkaloids. Leukopenia and neuromuscular toxicity were dose-limiting.
|
Authors | M A Cobleigh, S D Williams, L H Einhorn |
Journal | Cancer treatment reports
(Cancer Treat Rep)
1981 Jul-Aug
Vol. 65
Issue 7-8
Pg. 659-63
ISSN: 0361-5960 [Print] United States |
PMID | 7248983
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Breast Neoplasms
(drug therapy)
- Drug Administration Schedule
- Drug Evaluation
- Female
- Humans
- Leukopenia
(chemically induced)
- Neoplasm Metastasis
- Neuromuscular Diseases
(chemically induced)
- Prognosis
- Vinblastine
(adverse effects, analogs & derivatives, therapeutic use)
- Vindesine
|